Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.06 | -0.48% | -0.01 |
CRVS closed down 0.48 percent on Friday, May 24, 2024, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Jun 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Golden Cross | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.48% |
| Alert | Time |
|---|---|
| Possible NR7 | 3 days ago |
| Possible Inside Day | 3 days ago |
| Down 3% | 4 days ago |
| Down 2 % | 4 days ago |
| Down 1% | 4 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.19 |
| 52 Week Low | 1.05 |
| Average Volume | 252,154 |
| 200-Day Moving Average | 1.79 |
| 50-Day Moving Average | 1.79 |
| 20-Day Moving Average | 1.99 |
| 10-Day Moving Average | 2.18 |
| Average True Range | 0.18 |
| RSI (14) | 55.36 |
| ADX | 22.62 |
| +DI | 19.51 |
| -DI | 17.38 |
| Chandelier Exit (Long, 3 ATRs) | 1.81 |
| Chandelier Exit (Short, 3 ATRs) | 1.95 |
| Upper Bollinger Bands | 2.46 |
| Lower Bollinger Band | 1.52 |
| Percent B (%b) | 0.57 |
| BandWidth | 47.42 |
| MACD Line | 0.12 |
| MACD Signal Line | 0.12 |
| MACD Histogram | -0.0014 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.23 | ||||
| Resistance 3 (R3) | 2.22 | 2.17 | 2.20 | ||
| Resistance 2 (R2) | 2.17 | 2.12 | 2.17 | 2.19 | |
| Resistance 1 (R1) | 2.11 | 2.10 | 2.09 | 2.12 | 2.18 |
| Pivot Point | 2.06 | 2.06 | 2.04 | 2.06 | 2.06 |
| Support 1 (S1) | 2.00 | 2.01 | 1.98 | 2.01 | 1.94 |
| Support 2 (S2) | 1.95 | 1.99 | 1.95 | 1.93 | |
| Support 3 (S3) | 1.89 | 1.95 | 1.92 | ||
| Support 4 (S4) | 1.90 |
